Mark T. Fleming
About
Mark T. Fleming is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Mark T. Fleming has authored 125 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 32 papers in Surgery. Recurrent topics in Mark T. Fleming's work include Prostate Cancer Treatment and Research (45 papers), Bladder and Urothelial Cancer Treatments (31 papers) and Radiopharmaceutical Chemistry and Applications (28 papers). Mark T. Fleming is often cited by papers focused on Prostate Cancer Treatment and Research (45 papers), Bladder and Urothelial Cancer Treatments (31 papers) and Radiopharmaceutical Chemistry and Applications (28 papers). Mark T. Fleming collaborates with scholars based in United States, United Kingdom and Canada. Mark T. Fleming's co-authors include Howard I. Scher, Johann S. de Bono, Karim Fizazi, Fred Saad, Neal D. Shore, Andrew J. Armstrong, Mary‐Ellen Taplin, Cora N. Sternberg, Kim N. and Mohammad Hirmand and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Mark T. Fleming
125 papers receiving 6.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mark T. Fleming United States | 30 | 3.8k | 1.6k | 1.3k | 1.3k | 1.2k | 125 | 6.3k | ||
| David Harrington United States | 33 | 3.6k 1.0× | 3.8k 2.4× | 2.1k 1.6× | 285 0.2× | 772 0.6× | 133 | 8.3k | ||
| William K. Evans Canada | 56 | 4.4k 1.2× | 5.6k 3.6× | 1.6k 1.2× | 698 0.5× | 534 0.4× | 256 | 10.4k | ||
| Natasha B. Leighl Canada | 63 | 10.2k 2.7× | 10.5k 6.8× | 3.2k 2.4× | 994 0.8× | 3.2k 2.7× | 537 | 18.7k | ||
| Stephen H. Taplin United States | 56 | 1.8k 0.5× | 5.9k 3.8× | 322 0.2× | 1.1k 0.8× | 1.1k 1.0× | 169 | 9.3k | ||
| Lawrence N. Shulman United States | 57 | 2.1k 0.6× | 6.7k 4.3× | 1.2k 0.9× | 1.2k 0.9× | 2.4k 2.0× | 332 | 11.8k | ||
| Justin E. Bekelman United States | 39 | 1.5k 0.4× | 1.2k 0.8× | 135 0.1× | 650 0.5× | 426 0.4× | 207 | 5.8k | ||
| John Simes Australia | 41 | 2.5k 0.7× | 2.9k 1.8× | 734 0.6× | 480 0.4× | 984 0.8× | 172 | 9.1k | ||
| Joseph M. Unger United States | 51 | 1.9k 0.5× | 5.4k 3.5× | 971 0.7× | 708 0.5× | 1.2k 1.0× | 262 | 11.1k | ||
| William J. Mackillop Canada | 46 | 2.3k 0.6× | 2.8k 1.8× | 567 0.4× | 1.3k 1.0× | 1.0k 0.9× | 151 | 7.2k | ||
| Sarah Temin United States | 36 | 3.4k 0.9× | 5.8k 3.7× | 1.2k 0.9× | 795 0.6× | 2.0k 1.7× | 71 | 10.2k |
Countries citing papers authored by Mark T. Fleming
Since
Specialization
Citations
This map shows the geographic impact of Mark T. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Fleming more than expected).
Fields of papers citing papers by Mark T. Fleming
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark T. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Fleming. The network helps show where Mark T. Fleming may publish in the future.
Co-authorship network of co-authors of Mark T. Fleming
This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Fleming. A scholar is included among the top collaborators of Mark T. Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Fleming. Mark T. Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fizazi, Karim, K.N. Chi, Neal D. Shore, et al.. (2025). Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 36(11). 1319–1330.
2.
Martin, Julie Langan, et al.. (2024). Electroconvulsive Therapy (ECT): A Scotland Wide Naturalistic Study of 4,826 treatment episodes. European Psychiatry. 67(S1). S87–S87.
3.
Rais‐Bahrami, Soroush, Mark T. Fleming, Benjamin A. Gartrell, et al.. (2024). 18F-Flotufolastat Positron Emission Tomography in African American Patients With Suspected Prostate Cancer Recurrence: Findings From the Phase 3 SPOTLIGHT Study. Advances in Radiation Oncology. 9(9). 101571–101571.
4.
Fleming, Mark T., Rick Hermsen, Andrei S. Purysko, et al.. (2024). True-Positive18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. Journal of Nuclear Medicine. 65(7). 1080–1086.
5.
Slovin, Susan F., Karen E. Knudsen, Susan Halabi, et al.. (2023). Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 41(32). 5015–5024.
6.
Bono, Johann S. de, Mark T. Fleming, Judy S. Wang, et al.. (2021). Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical Cancer Research. 27(13). 3602–3609.
7.
Gupta, Shilpa, Luke T. Nordquist, Mark T. Fleming, et al.. (2018). Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. Clinical Cancer Research. 24(21). 5225–5232.
8.
Powles, Thomas, Jürgen E. Gschwend, Yohann Loriot, et al.. (2017). Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial. Annals of Oncology. 28. v326–v326.
9.
Morris, Michael J., Dana E. Rathkopf, William Novotny, et al.. (2016). Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(15). 3774–3781.
10.
Bishop, Andrea & Mark T. Fleming. (2014). Patient Safety and Engagement at the Frontlines of Healthcare. Healthcare Quarterly. 17(SP). 36–40.
11.
Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2012). Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine. 367(13). 1187–1197.
12.
Sonpavde, Guru, В. Б. Матвеев, John M. Burke, et al.. (2011). Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Annals of Oncology. 23(7). 1803–1808.
13.
Dunphy, Bruce C., et al.. (2010). Evidence based-practice and affect : the impact of physician attitudes on outcomes associated with clinical reasoning and decision-making. 10. 56–64.
14.
Galsky, Matthew D., Daniel D. Von Hoff, Marcus A. Neubauer, et al.. (2010). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs. 30(2). 695–701.
15.
Sonpavde, Guru, Phillip Periman, Douglas Weckstein, et al.. (2009). Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Annals of Oncology. 21(2). 319–324.
16.
Golden, Matthew R., Julia C. Dombrowski, Robert W. Wood, Mark T. Fleming, & Robert Harrington. (2008). A controlled study of the effectiveness of public health HIV partner notification services. AIDS. 23(1). 133–135.
17.
Golden, Matthew R., Robert W. Wood, Susan E. Buskin, Mark T. Fleming, & Robert Harrington. (2007). Ongoing Risk Behavior Among Persons With HIV in Medical Care. AIDS and Behavior. 11(5). 726–735.
18.
Fleming, Mark T., Michael J. Morris, Glenn Heller, & Howard I. Scher. (2006). Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nature Clinical Practice Oncology. 3(12). 658–667.
19.
Murphy, Andrea, et al.. (2006). Drug information resources used by nurse practitioners and collaborating physicians at the point of care in Nova Scotia, Canada: a survey and review of the literature. BMC Nursing. 5(1). 5–5.
20.
Matlow, Anne, Virginia Flintoft, Elaine Orrbine, et al.. (2005). The Development of the Canadian Paediatric Trigger Tool for Identifying Potential Adverse Events. Healthcare Quarterly. 8(sp). 90–93.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by David Harrington Breakdown of academic impact, for papers by William K. Evans Breakdown of academic impact, for papers by Natasha B. Leighl Breakdown of academic impact, for papers by Stephen H. Taplin Breakdown of academic impact, for papers by Lawrence N. Shulman Breakdown of academic impact, for papers by Justin E. Bekelman Breakdown of academic impact, for papers by John Simes Breakdown of academic impact, for papers by Joseph M. Unger Breakdown of academic impact, for papers by William J. Mackillop Breakdown of academic impact, for papers by Sarah Temin